New cocktail aims to boost immune attack on ovarian cancer

NCT ID NCT05231122

Recruiting now Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or peritoneal cancer will be randomly assigned to receive the two-drug or three-drug combination. The study measures tumor response, side effects, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab, bevacizumab, and anti-CD40 antibody CDX-1140
What this could lead to: If successful, this could offer a new treatment option for recurrent ovarian cancer, potentially shrinking tumors and extending survival.
What could go wrong: This is an early Phase 2 trial with only 80 participants, so results may not apply to all patients. The added drug CDX-1140 could cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CLEAR CELL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma fallopian tube cancer fallopian tube carcinoma fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian carcinoma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.